Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study

BACKGROUND: Clinical guidelines advise osimertinib as preferred first line treatment for advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with deletions in exon 19 (del19) or exon 21 L858R mutation. However, for first-line osimertinib the real world overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Gijtenbeek, Rolof G.P., Damhuis, Ronald A.M., van der Wekken, Anthonie J., Hendriks, Lizza E.L., Groen, Harry J.M., van Geffen, Wouter H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932646/
https://www.ncbi.nlm.nih.gov/pubmed/36817181
http://dx.doi.org/10.1016/j.lanepe.2023.100592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932646/
https://www.ncbi.nlm.nih.gov/pubmed/36817181
http://dx.doi.org/10.1016/j.lanepe.2023.100592

Ejemplares similares